ロード中...
The Emergence of Biosimilar Insulin Preparations—A Cause for Concern?
Several biopharmaceuticals, including insulin and insulin analogs, are, or shortly will be, off-patent, thereby providing an opportunity for companies to attempt to manufacture “copies” commonly referred to as biosimilars and also known as follow-on biologics. Reassurance that such copy biologics ar...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Mary Ann Liebert, Inc.
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3698679/ https://ncbi.nlm.nih.gov/pubmed/23046400 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/dia.2012.0105 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|